 Sarah Parker
Concepts (344)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimicrobial Stewardship | 11 | 2021 | 129 | 4.530 |
Why?
| | Hospitals, Pediatric | 22 | 2022 | 557 | 3.500 |
Why?
| | Anti-Infective Agents | 12 | 2021 | 242 | 3.380 |
Why?
| | Anti-Bacterial Agents | 34 | 2024 | 1928 | 2.940 |
Why?
| | Bacteremia | 4 | 2025 | 222 | 2.100 |
Why?
| | Osteomyelitis | 9 | 2024 | 141 | 2.040 |
Why?
| | Arthritis, Infectious | 7 | 2022 | 72 | 1.880 |
Why?
| | Drug Utilization Review | 6 | 2020 | 61 | 1.560 |
Why?
| | Bacterial Infections | 7 | 2025 | 247 | 1.400 |
Why?
| | Blood Culture | 4 | 2025 | 25 | 1.380 |
Why?
| | Metronidazole | 3 | 2019 | 20 | 1.190 |
Why?
| | Appendicitis | 3 | 2019 | 150 | 1.060 |
Why?
| | Child | 50 | 2026 | 22600 | 1.020 |
Why?
| | Staphylococcal Infections | 5 | 2025 | 388 | 1.000 |
Why?
| | Otitis Media | 4 | 2024 | 180 | 0.990 |
Why?
| | Acute Disease | 8 | 2025 | 1029 | 0.920 |
Why?
| | Kingella kingae | 2 | 2022 | 12 | 0.850 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2025 | 287 | 0.830 |
Why?
| | Respiration, Artificial | 3 | 2026 | 710 | 0.800 |
Why?
| | Retrospective Studies | 27 | 2025 | 17149 | 0.710 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2025 | 248 | 0.690 |
Why?
| | Musculoskeletal System | 1 | 2022 | 53 | 0.680 |
Why?
| | Musculoskeletal Diseases | 2 | 2025 | 90 | 0.670 |
Why?
| | Surgical Wound Infection | 2 | 2022 | 330 | 0.640 |
Why?
| | Humans | 75 | 2026 | 144667 | 0.580 |
Why?
| | Infant | 22 | 2026 | 10023 | 0.570 |
Why?
| | Respiratory Tract Infections | 1 | 2022 | 395 | 0.540 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 200 | 0.530 |
Why?
| | Drug Resistance, Bacterial | 3 | 2021 | 205 | 0.520 |
Why?
| | Medical Order Entry Systems | 1 | 2018 | 40 | 0.520 |
Why?
| | Cefoxitin | 1 | 2017 | 8 | 0.510 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2017 | 49 | 0.510 |
Why?
| | Cephalosporins | 2 | 2015 | 47 | 0.510 |
Why?
| | Ceftriaxone | 1 | 2017 | 21 | 0.510 |
Why?
| | Microbial Sensitivity Tests | 5 | 2024 | 373 | 0.510 |
Why?
| | Child, Preschool | 19 | 2026 | 11790 | 0.500 |
Why?
| | beta-Lactams | 1 | 2017 | 32 | 0.500 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2017 | 70 | 0.490 |
Why?
| | Interprofessional Relations | 1 | 2019 | 275 | 0.490 |
Why?
| | Prescriptions | 1 | 2016 | 75 | 0.480 |
Why?
| | Pneumonia, Bacterial | 1 | 2017 | 113 | 0.480 |
Why?
| | Drug Costs | 1 | 2017 | 117 | 0.480 |
Why?
| | Pyomyositis | 3 | 2022 | 15 | 0.480 |
Why?
| | Communicable Diseases | 4 | 2021 | 166 | 0.460 |
Why?
| | Exanthema | 1 | 2016 | 84 | 0.460 |
Why?
| | Neutropenia | 1 | 2016 | 155 | 0.450 |
Why?
| | Diarrhea | 1 | 2016 | 192 | 0.440 |
Why?
| | Thimerosal | 2 | 2005 | 6 | 0.440 |
Why?
| | Mycobacterium tuberculosis | 4 | 2021 | 337 | 0.440 |
Why?
| | Health Resources | 1 | 2016 | 130 | 0.430 |
Why?
| | Preservatives, Pharmaceutical | 2 | 2005 | 28 | 0.420 |
Why?
| | Enterovirus D, Human | 1 | 2016 | 87 | 0.420 |
Why?
| | Inpatients | 4 | 2021 | 547 | 0.420 |
Why?
| | Disease Outbreaks | 2 | 2021 | 423 | 0.400 |
Why?
| | Decision Support Systems, Clinical | 1 | 2018 | 269 | 0.400 |
Why?
| | Enterovirus Infections | 1 | 2016 | 173 | 0.390 |
Why?
| | Cephalexin | 2 | 2024 | 14 | 0.390 |
Why?
| | Electronic Health Records | 2 | 2019 | 1176 | 0.380 |
Why?
| | Inappropriate Prescribing | 1 | 2013 | 65 | 0.380 |
Why?
| | Guideline Adherence | 1 | 2017 | 586 | 0.380 |
Why?
| | Pandemics | 2 | 2022 | 1700 | 0.370 |
Why?
| | Cross Infection | 3 | 2025 | 263 | 0.370 |
Why?
| | Trachea | 2 | 2026 | 258 | 0.360 |
Why?
| | Intensive Care Units, Pediatric | 3 | 2025 | 288 | 0.340 |
Why?
| | Health Personnel | 1 | 2018 | 746 | 0.340 |
Why?
| | Referral and Consultation | 1 | 2017 | 852 | 0.330 |
Why?
| | Vancomycin | 2 | 2023 | 94 | 0.320 |
Why?
| | Liver Abscess, Amebic | 2 | 2009 | 3 | 0.310 |
Why?
| | Phospholipases A | 2 | 2007 | 97 | 0.300 |
Why?
| | Urinary Tract Infections | 2 | 2025 | 206 | 0.300 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1569 | 0.300 |
Why?
| | Stomach Rupture | 1 | 2009 | 3 | 0.290 |
Why?
| | Phospholipases | 1 | 2009 | 14 | 0.290 |
Why?
| | Thiolester Hydrolases | 1 | 2009 | 13 | 0.290 |
Why?
| | Pericardial Effusion | 1 | 2009 | 21 | 0.290 |
Why?
| | Male | 27 | 2025 | 72431 | 0.280 |
Why?
| | Lactones | 1 | 2009 | 59 | 0.280 |
Why?
| | Staphylococcus aureus | 5 | 2024 | 454 | 0.280 |
Why?
| | Peritonitis | 1 | 2009 | 83 | 0.280 |
Why?
| | Pleural Effusion | 1 | 2009 | 59 | 0.270 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2005 | 28 | 0.270 |
Why?
| | Drug Utilization | 3 | 2017 | 167 | 0.270 |
Why?
| | Colorado | 4 | 2020 | 4558 | 0.270 |
Why?
| | Cefadroxil | 2 | 2024 | 8 | 0.260 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2007 | 23 | 0.250 |
Why?
| | Cost Savings | 2 | 2017 | 85 | 0.250 |
Why?
| | Gene Expression Regulation, Bacterial | 2 | 2009 | 344 | 0.250 |
Why?
| | Female | 24 | 2025 | 78304 | 0.240 |
Why?
| | Time Factors | 4 | 2024 | 7140 | 0.240 |
Why?
| | Dermatomycoses | 1 | 2006 | 8 | 0.240 |
Why?
| | Pharmacy Service, Hospital | 2 | 2017 | 81 | 0.240 |
Why?
| | Infant, Newborn | 7 | 2025 | 6399 | 0.240 |
Why?
| | Adolescent | 15 | 2025 | 22409 | 0.230 |
Why?
| | Drug Approval | 1 | 2006 | 91 | 0.230 |
Why?
| | Mycobacterium | 1 | 2007 | 116 | 0.230 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2006 | 133 | 0.230 |
Why?
| | Intellectual Property | 1 | 2005 | 7 | 0.220 |
Why?
| | Infection Control | 3 | 2015 | 174 | 0.220 |
Why?
| | Autistic Disorder | 2 | 2005 | 211 | 0.220 |
Why?
| | Measles | 1 | 2025 | 46 | 0.210 |
Why?
| | Specimen Handling | 1 | 2026 | 187 | 0.210 |
Why?
| | Mycoses | 1 | 2025 | 88 | 0.210 |
Why?
| | Simplexvirus | 1 | 2004 | 82 | 0.210 |
Why?
| | Encephalitis, Viral | 1 | 2004 | 45 | 0.210 |
Why?
| | Limbus Corneae | 1 | 2023 | 8 | 0.200 |
Why?
| | Bacterial Proteins | 2 | 2018 | 981 | 0.200 |
Why?
| | Amoxicillin | 1 | 2024 | 35 | 0.200 |
Why?
| | Herpes Simplex | 1 | 2004 | 98 | 0.200 |
Why?
| | Lymphadenitis | 1 | 2023 | 6 | 0.190 |
Why?
| | Drug Administration Schedule | 3 | 2017 | 779 | 0.190 |
Why?
| | Hospitalization | 5 | 2023 | 2446 | 0.190 |
Why?
| | Drainage | 2 | 2017 | 184 | 0.190 |
Why?
| | Cisplatin | 1 | 2024 | 339 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 171 | 0.190 |
Why?
| | Exosomes | 1 | 2023 | 104 | 0.180 |
Why?
| | Databases, Factual | 4 | 2025 | 1494 | 0.180 |
Why?
| | Exudates and Transudates | 1 | 2021 | 12 | 0.180 |
Why?
| | Machine Learning | 2 | 2025 | 587 | 0.180 |
Why?
| | Cross-Over Studies | 1 | 2024 | 605 | 0.170 |
Why?
| | Immunotherapy | 1 | 2006 | 662 | 0.170 |
Why?
| | Fluoroquinolones | 1 | 2021 | 45 | 0.170 |
Why?
| | Risk Adjustment | 1 | 2021 | 85 | 0.170 |
Why?
| | Fever | 2 | 2017 | 313 | 0.160 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 94 | 0.160 |
Why?
| | Antibiotic Prophylaxis | 1 | 2022 | 134 | 0.160 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.160 |
Why?
| | Hospitals | 3 | 2021 | 729 | 0.160 |
Why?
| | Delayed Diagnosis | 1 | 2021 | 98 | 0.160 |
Why?
| | Treatment Outcome | 7 | 2024 | 11735 | 0.160 |
Why?
| | Meningitis | 1 | 2021 | 80 | 0.160 |
Why?
| | Laboratories | 1 | 2021 | 110 | 0.160 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2020 | 104 | 0.150 |
Why?
| | Bacteroides fragilis | 1 | 2019 | 14 | 0.150 |
Why?
| | Encephalitis | 1 | 2021 | 142 | 0.150 |
Why?
| | Appendectomy | 2 | 2017 | 90 | 0.150 |
Why?
| | Monte Carlo Method | 1 | 2019 | 153 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 881 | 0.150 |
Why?
| | Autophagy | 1 | 2021 | 284 | 0.140 |
Why?
| | Neisseriaceae Infections | 1 | 2018 | 6 | 0.140 |
Why?
| | Pediatrics | 3 | 2017 | 1121 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 1505 | 0.140 |
Why?
| | Area Under Curve | 1 | 2019 | 329 | 0.140 |
Why?
| | Entamoeba histolytica | 2 | 2009 | 9 | 0.140 |
Why?
| | Hospital Records | 1 | 2018 | 10 | 0.140 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 601 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1183 | 0.140 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 1044 | 0.140 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 269 | 0.140 |
Why?
| | Medical Records Systems, Computerized | 1 | 2018 | 94 | 0.130 |
Why?
| | Hydrolysis | 2 | 2009 | 198 | 0.130 |
Why?
| | Tuberculosis | 1 | 2021 | 291 | 0.130 |
Why?
| | Sequence Homology, Amino Acid | 2 | 2009 | 393 | 0.130 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1268 | 0.130 |
Why?
| | Patient Readmission | 3 | 2017 | 765 | 0.130 |
Why?
| | MicroRNAs | 1 | 2023 | 689 | 0.130 |
Why?
| | Abdominal Abscess | 1 | 2017 | 25 | 0.130 |
Why?
| | Abscess | 1 | 2017 | 76 | 0.130 |
Why?
| | Central Venous Catheters | 1 | 2017 | 52 | 0.120 |
Why?
| | Administration, Oral | 2 | 2016 | 851 | 0.120 |
Why?
| | Medical Records | 1 | 2017 | 191 | 0.120 |
Why?
| | Communicable Disease Control | 1 | 2017 | 86 | 0.120 |
Why?
| | Drug Substitution | 1 | 2017 | 63 | 0.120 |
Why?
| | Drug Resistance | 1 | 2017 | 145 | 0.120 |
Why?
| | Pharmacists | 1 | 2019 | 240 | 0.120 |
Why?
| | Amino Acid Sequence | 4 | 2009 | 2136 | 0.120 |
Why?
| | Osteoarthritis | 1 | 2018 | 196 | 0.120 |
Why?
| | Drug Prescriptions | 1 | 2018 | 283 | 0.120 |
Why?
| | Molecular Sequence Data | 4 | 2009 | 2909 | 0.120 |
Why?
| | Rural Population | 1 | 2021 | 657 | 0.120 |
Why?
| | Aftercare | 1 | 2017 | 222 | 0.110 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 1995 | 0.110 |
Why?
| | Administration, Intravenous | 1 | 2016 | 170 | 0.110 |
Why?
| | Cell Wall | 2 | 2021 | 59 | 0.110 |
Why?
| | Community-Acquired Infections | 1 | 2017 | 175 | 0.110 |
Why?
| | Length of Stay | 2 | 2020 | 1339 | 0.110 |
Why?
| | United States | 9 | 2025 | 16018 | 0.110 |
Why?
| | Knowledge Management | 1 | 2014 | 2 | 0.110 |
Why?
| | Radiography | 1 | 2017 | 848 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1076 | 0.110 |
Why?
| | Clostridium Infections | 1 | 2015 | 74 | 0.110 |
Why?
| | Prospective Studies | 3 | 2024 | 7994 | 0.100 |
Why?
| | Medication Therapy Management | 1 | 2014 | 72 | 0.100 |
Why?
| | Postoperative Care | 1 | 2016 | 286 | 0.100 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 638 | 0.100 |
Why?
| | Antitubercular Agents | 2 | 2021 | 216 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2201 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 869 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 3 | 2009 | 2754 | 0.090 |
Why?
| | Drug Monitoring | 1 | 2016 | 396 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2017 | 607 | 0.090 |
Why?
| | Quality of Health Care | 1 | 2017 | 692 | 0.090 |
Why?
| | Genotype | 3 | 2021 | 1847 | 0.090 |
Why?
| | Drug Hypersensitivity | 1 | 2013 | 89 | 0.090 |
Why?
| | Laparoscopy | 1 | 2017 | 477 | 0.090 |
Why?
| | Risk Assessment | 2 | 2016 | 3729 | 0.090 |
Why?
| | Bacteria | 3 | 2023 | 894 | 0.090 |
Why?
| | Physicians | 1 | 2019 | 949 | 0.080 |
Why?
| | Cohort Studies | 2 | 2017 | 5957 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2014 | 771 | 0.070 |
Why?
| | Paromomycin | 1 | 2009 | 3 | 0.070 |
Why?
| | Mycolic Acids | 1 | 2009 | 7 | 0.070 |
Why?
| | Trophozoites | 1 | 2009 | 4 | 0.070 |
Why?
| | Young Adult | 4 | 2021 | 14122 | 0.070 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1180 | 0.070 |
Why?
| | Antiprotozoal Agents | 1 | 2009 | 15 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1360 | 0.070 |
Why?
| | DNA, Protozoan | 1 | 2008 | 32 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2019 | 0.070 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2009 | 131 | 0.070 |
Why?
| | Nitrobenzenes | 1 | 2007 | 16 | 0.060 |
Why?
| | Chromatography, Thin Layer | 1 | 2007 | 25 | 0.060 |
Why?
| | Polysorbates | 1 | 2007 | 42 | 0.060 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 3523 | 0.060 |
Why?
| | Terminology as Topic | 1 | 2009 | 255 | 0.060 |
Why?
| | Injections, Intravenous | 2 | 2017 | 198 | 0.060 |
Why?
| | Gentian Violet | 1 | 2026 | 4 | 0.060 |
Why?
| | Membrane Lipids | 1 | 2007 | 82 | 0.060 |
Why?
| | Phenazines | 1 | 2026 | 17 | 0.060 |
Why?
| | Animals | 6 | 2024 | 37948 | 0.060 |
Why?
| | Selection, Genetic | 1 | 2008 | 256 | 0.060 |
Why?
| | Maximum Tolerated Dose | 1 | 2006 | 211 | 0.060 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1363 | 0.060 |
Why?
| | Measles Vaccine | 1 | 2025 | 19 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 820 | 0.060 |
Why?
| | United States Food and Drug Administration | 1 | 2006 | 205 | 0.060 |
Why?
| | Aminopeptidases | 1 | 2024 | 21 | 0.050 |
Why?
| | Ethylmercury Compounds | 1 | 2004 | 1 | 0.050 |
Why?
| | Diphtheria-Tetanus Vaccine | 1 | 2004 | 5 | 0.050 |
Why?
| | Risk Factors | 2 | 2016 | 10796 | 0.050 |
Why?
| | Methylmercury Compounds | 1 | 2004 | 8 | 0.050 |
Why?
| | Drug Industry | 1 | 2005 | 49 | 0.050 |
Why?
| | Mass Spectrometry | 2 | 2025 | 743 | 0.050 |
Why?
| | Aphasia | 1 | 2004 | 24 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1501 | 0.050 |
Why?
| | Half-Life | 1 | 2004 | 152 | 0.050 |
Why?
| | North America | 1 | 2025 | 312 | 0.050 |
Why?
| | Patient Discharge | 2 | 2025 | 985 | 0.050 |
Why?
| | Streptococcus pyogenes | 1 | 2004 | 41 | 0.050 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 16 | 0.050 |
Why?
| | Acyclovir | 1 | 2004 | 96 | 0.050 |
Why?
| | Escherichia coli | 1 | 2009 | 854 | 0.050 |
Why?
| | Adult | 5 | 2021 | 40489 | 0.050 |
Why?
| | Child Development Disorders, Pervasive | 1 | 2004 | 62 | 0.050 |
Why?
| | Hematologic Neoplasms | 1 | 2006 | 163 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2023 | 3414 | 0.050 |
Why?
| | Vomiting | 1 | 2004 | 131 | 0.050 |
Why?
| | beta-Lactamases | 1 | 2024 | 52 | 0.050 |
Why?
| | Kinetics | 1 | 2007 | 1602 | 0.050 |
Why?
| | Sulbactam | 1 | 2023 | 6 | 0.050 |
Why?
| | Ampicillin | 1 | 2023 | 16 | 0.050 |
Why?
| | Stromal Cells | 1 | 2023 | 120 | 0.050 |
Why?
| | Nasopharynx | 1 | 2023 | 73 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2023 | 67 | 0.050 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2023 | 54 | 0.050 |
Why?
| | Pneumonia | 1 | 2009 | 629 | 0.050 |
Why?
| | Cephalothin | 1 | 2022 | 5 | 0.050 |
Why?
| | Oxacillin | 1 | 2022 | 5 | 0.050 |
Why?
| | Type C Phospholipases | 1 | 2002 | 69 | 0.050 |
Why?
| | Methicillin | 1 | 2022 | 10 | 0.050 |
Why?
| | Cefazolin | 1 | 2022 | 22 | 0.050 |
Why?
| | Cornea | 1 | 2023 | 154 | 0.050 |
Why?
| | Butanes | 1 | 2021 | 4 | 0.040 |
Why?
| | Cell Extracts | 1 | 2021 | 21 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 357 | 0.040 |
Why?
| | DNA Glycosylases | 1 | 2021 | 10 | 0.040 |
Why?
| | Gestational Age | 1 | 2025 | 980 | 0.040 |
Why?
| | Cell Communication | 1 | 2023 | 325 | 0.040 |
Why?
| | Ubiquinone | 1 | 2021 | 35 | 0.040 |
Why?
| | Pyridinium Compounds | 1 | 2021 | 31 | 0.040 |
Why?
| | Streptococcus pneumoniae | 1 | 2023 | 176 | 0.040 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 46 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2004 | 279 | 0.040 |
Why?
| | Megakaryocytes | 1 | 2021 | 34 | 0.040 |
Why?
| | Arkansas | 1 | 2021 | 23 | 0.040 |
Why?
| | Reference Standards | 1 | 2021 | 178 | 0.040 |
Why?
| | Microbiology | 1 | 2021 | 24 | 0.040 |
Why?
| | Organophosphorus Compounds | 1 | 2021 | 84 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2021 | 153 | 0.040 |
Why?
| | Seizures | 1 | 2004 | 477 | 0.040 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2021 | 168 | 0.040 |
Why?
| | Drug Combinations | 1 | 2021 | 393 | 0.040 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2021 | 191 | 0.040 |
Why?
| | Myositis | 1 | 2020 | 57 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2021 | 246 | 0.040 |
Why?
| | Pseudomonas aeruginosa | 1 | 2002 | 391 | 0.040 |
Why?
| | Neoplasms | 2 | 2025 | 2873 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2020 | 177 | 0.040 |
Why?
| | Clindamycin | 1 | 2018 | 14 | 0.040 |
Why?
| | Feces | 2 | 2015 | 513 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 1437 | 0.030 |
Why?
| | Developed Countries | 1 | 2018 | 38 | 0.030 |
Why?
| | Hospital Charges | 1 | 2018 | 46 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2021 | 572 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5870 | 0.030 |
Why?
| | Methyltransferases | 1 | 2018 | 75 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 2018 | 68 | 0.030 |
Why?
| | Research Design | 1 | 2004 | 1129 | 0.030 |
Why?
| | Medical Staff, Hospital | 1 | 2018 | 80 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2025 | 978 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 15 | 0.030 |
Why?
| | Metformin | 1 | 2021 | 320 | 0.030 |
Why?
| | Age Distribution | 1 | 2018 | 402 | 0.030 |
Why?
| | Blood Platelets | 1 | 2021 | 379 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 386 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2023 | 1106 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1170 | 0.030 |
Why?
| | Benchmarking | 1 | 2018 | 189 | 0.030 |
Why?
| | Vaccination | 1 | 2025 | 1419 | 0.030 |
Why?
| | Mice | 2 | 2021 | 18261 | 0.030 |
Why?
| | Myocardium | 1 | 2021 | 928 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1652 | 0.030 |
Why?
| | Genomics | 1 | 2021 | 831 | 0.030 |
Why?
| | Lung | 1 | 2009 | 4089 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2016 | 249 | 0.030 |
Why?
| | Algorithms | 1 | 2023 | 1844 | 0.030 |
Why?
| | Asthma | 1 | 2006 | 1774 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1136 | 0.030 |
Why?
| | Alcoholism | 1 | 2021 | 813 | 0.030 |
Why?
| | Inservice Training | 1 | 2014 | 118 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 2137 | 0.020 |
Why?
| | Kidney | 1 | 2021 | 1495 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2021 | 2037 | 0.020 |
Why?
| | Substrate Specificity | 2 | 2004 | 392 | 0.020 |
Why?
| | Medical Oncology | 1 | 2015 | 331 | 0.020 |
Why?
| | Brain | 1 | 2004 | 2934 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1388 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4539 | 0.020 |
Why?
| | Dysentery, Amebic | 1 | 2008 | 2 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 6041 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3603 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1047 | 0.010 |
Why?
| | Prophages | 1 | 2004 | 9 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2016 | 2950 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 564 | 0.010 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2002 | 141 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 324 | 0.010 |
Why?
| | Choline | 1 | 2002 | 136 | 0.010 |
Why?
| | Alleles | 1 | 2004 | 886 | 0.010 |
Why?
| | Phospholipids | 1 | 2002 | 214 | 0.010 |
Why?
| | Hemolysis | 1 | 2002 | 242 | 0.010 |
Why?
| | Base Sequence | 1 | 2004 | 2177 | 0.010 |
Why?
| | Calcium | 1 | 2002 | 1182 | 0.010 |
Why?
| | Aged | 1 | 2009 | 25955 | 0.000 |
Why?
| | Middle Aged | 1 | 2009 | 35971 | 0.000 |
Why?
|
|
Parker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|